Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19

Having trouble viewing this email? View it as a Web page. You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).   Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19 01/27/2022 06:30 PM EST NIH trial compared hIVIG plus remdesivir to remdesivir alone. Update Your E-mail Address | Add Subscriptions | Unsubscribe All If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. For all other inquiries about NIH programs and activities, please contact Ask NIH. Before writing, please view our Frequently Asked Questions page, our Health Information page, or Search our website. This service is provided to you by the National Institutes of Health. NIH…Turning Discovery Into Health®  This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Institutes of Health (NIH) · 9000 Rockville Pike · Bethesda MD 20892 · 301-496-4000 / TTY 301-402-9612